Sigma Genetics

High-Level Overview

Sigma Genetics is a biotechnology company developing a next-generation intracellular delivery platform called Magnetoporation, which uses magnetic fields to deliver DNA, RNA, and other charged molecules into cells. This technology enables scalable, high-efficiency cell engineering aimed at advancing therapeutics, including cell and gene therapies, immunotherapies, blood products, and synthetic biology. Their platform addresses critical challenges in gene delivery such as efficiency, cell viability, and scalability, positioning Sigma Genetics as a foundational technology provider for the future of cell and gene therapy manufacturing[1][2][3][4].

The company primarily serves biopharma developers, researchers, and manufacturers who require improved gene delivery methods to create life-saving therapies. By enabling faster, safer, and more cost-effective intracellular delivery, Sigma Genetics solves the problem of inefficient and damaging gene transfer methods currently limiting the development and scale-up of advanced cell therapies. Their growth momentum is reflected in their prototype-ready stage, ongoing development of the Magnetoporator™ device, and participation in leading biotech startup networks[2][3][4].

Origin Story

Founded in November 2016 in Seattle, WA, Sigma Genetics was co-founded by Karen Eaton (Founder/CEO), Matthew Scholz, and Chris Pihl. Karen Eaton brings a scientific and business background focused on advancing healthcare through biotechnology. Matthew Scholz is a serial entrepreneur with deep expertise in gene therapy and holds numerous patents in transfection technologies and therapeutic innovations. The idea emerged from the need to overcome the limitations of conventional gene delivery techniques like electroporation, which suffer from issues such as cell damage and poor scalability. Early traction includes developing the Magnetoporator™ platform that uses pulsed magnetic fields to induce nanosecond pulsed electric fields (nsPEF), enabling efficient and non-invasive intracellular delivery across various cell types[2][3][4].

Core Differentiators

• Unique Technology: Magnetoporation uses magnetic fields to induce nsPEF for intracellular delivery, avoiding arcing and cell damage common in electroporation.
• Scalability: The platform supports gene delivery from single cells to large-scale manufacturing, addressing a major bottleneck in cell therapy production.
• Non-Invasive & Versatile: Suitable for in vivo applications and a wide range of payloads including DNA, RNA, and proteins.
• Efficiency & Safety: Increases gene transfer efficiency while minimizing cell death, enabling safer and more effective therapies.
• Broad Application: Applicable to immunotherapies, cancer drug delivery, DNA vaccines, biopharma manufacturing, and synthetic biology.
• Experienced Founders: Leadership with strong backgrounds in gene therapy, entrepreneurship, and patented innovations in biotechnology[1][2][3][4].

Role in the Broader Tech Landscape

Sigma Genetics is riding the wave of rapid growth in cell and gene therapy markets, projected to become multi-trillion dollar industries. The timing is critical as current gene delivery methods limit the scalability and safety of advanced therapies. Their magnetic field-based delivery platform addresses these market forces by enabling more efficient, scalable, and cost-effective manufacturing of cell and gene therapies. This technology not only accelerates therapeutic development but also influences the broader ecosystem by providing a foundational tool that can be integrated across drug discovery, biomanufacturing, and synthetic biology sectors. Their innovation supports the trend toward personalized medicine and next-generation biologics[1][2][3][4].

Quick Take & Future Outlook

Looking ahead, Sigma Genetics is poised to advance from prototype to commercial deployment, potentially becoming a key enabler in the cell and gene therapy manufacturing supply chain. Trends such as increasing demand for personalized and cell-based therapies, improvements in gene editing, and biomanufacturing scale-up will shape their journey. Their influence may expand as they refine their platform, form strategic partnerships, and demonstrate clinical and commercial success. Ultimately, Sigma Genetics could become a foundational technology provider powering safer, faster, and more accessible gene and cell therapies worldwide, fulfilling their mission to transform intracellular delivery and therapeutic manufacturing[1][2][4].